EUVIMEDEUVIMED entdecken
Crossref

Network pharmacology-based identification and analysis of key gene targets for notoginsenoside R1 in breast neoplasms treatment

Yue-Er Liu, Xiao Zhang

New Discovery · 2025

DOI: 10.61958/ewny9244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New Discovery, 2025. Verfasst von Yue-Er Liu und 1 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to systematically identify and analyze the key gene targets of notoginsenoside R1 (NGR1) in treating breast neoplasms using a network pharmacology approach, so as to provide a theoretical foundation for further clinical application.

Methods

We initially retrieved target data associated with breast tissue, breast neoplasms, and NGR1 from databases such as Medical Subject Headings (MeSH), GeneCards, Traditional Chinese Medicine Systems pharmacology (TCSMP), The Encyclopedia of Traditional Chinese Medicine (ETCM), and A high-throughput experiment- and reference-guided database of traditional Chinese medicine (Herb). Intersection gene targets were identified through Venn analysis, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The STRING database and Cytoscape were utilized to construct and visualize a protein-protein interaction (PPI) network.

Results

Venn analysis identified 36 crucial gene targets that shared by breast tissue, breast neoplasms, and NGR1. These genes were significantly enriched in pathways integral to tumor biology, including cell proliferation, apoptosis, inflammatory responses, and tumor microenvironment regulation. Notably, AKT serine/threonine kinase 1 (AKT1), interleukin 6 (IL6), caspase-3 (CASP3), estrogen receptor 1 (ESR1), tumor necrosis factor (TNF), and interleukin 1 beta (IL1B) emerged as pivotal nodes in the PPI network, suggesting their potential roles in breast neoplasms progression and treatment.

Conclusions

This study provides a foundation for developing targeted therapies, as modulation by NGR1 could potentially disrupt critical pathways driving tumor growth and survival. This insight into the molecular mechanisms of NGR1 may inform the design of more effective treatment strategies for breast neoplasms and emphasize the potential of personalized medicine approaches.

Zitieren

APA

Liu, Y., & Zhang, X. (2025). Network pharmacology-based identification and analysis of key gene targets for notoginsenoside R1 in breast neoplasms treatment. New Discovery. https://doi.org/10.61958/ewny9244

Vancouver

Liu Y, Zhang X. Network pharmacology-based identification and analysis of key gene targets for notoginsenoside R1 in breast neoplasms treatment. New Discovery. 2025. doi:10.61958/ewny9244

BibTeX
@article{Liu2025,
  author = {Liu, Yue-Er and Zhang, Xiao},
  title = {Network pharmacology-based identification and analysis of key gene targets for notoginsenoside R1 in breast neoplasms treatment},
  journal = {New Discovery},
  year = {2025},
  doi = {10.61958/ewny9244}
}
Kostenlos starten →